Kymera Therapeutics (NASDAQ:KYMR – Get Rating) and Opthea (NASDAQ:OPT – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.
Valuation & Earnings
This table compares Kymera Therapeutics and Opthea’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Kymera Therapeutics||$72.83 million||13.52||-$100.22 million||($2.48)||-7.68|
This table compares Kymera Therapeutics and Opthea’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Kymera Therapeutics has a beta of 2.2, meaning that its stock price is 120% more volatile than the S&P 500. Comparatively, Opthea has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for Kymera Therapeutics and Opthea, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Kymera Therapeutics presently has a consensus price target of $70.00, suggesting a potential upside of 267.65%. Opthea has a consensus price target of $19.00, suggesting a potential upside of 227.02%. Given Kymera Therapeutics’ higher probable upside, equities analysts clearly believe Kymera Therapeutics is more favorable than Opthea.
Institutional and Insider Ownership
77.7% of Kymera Therapeutics shares are owned by institutional investors. Comparatively, 12.8% of Opthea shares are owned by institutional investors. 23.3% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Kymera Therapeutics Company Profile (Get Rating)
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Opthea Company Profile (Get Rating)
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.